Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > What data and results are we waiting for?
View:
Post by westcoast1000 on Sep 09, 2022 12:06pm

What data and results are we waiting for?

Coudl Notable or CF please provide a quick summary of what data and results we are waiting for in the next 6 months?

Thanks for any guidance.
Comment by westcoast1000 on Sep 09, 2022 12:55pm
Correction:  Noteable, NOT Notable.
Comment by Capitalista on Sep 09, 2022 1:09pm
There's a good summary in the latest corporate presentation on the ONC website.  
Comment by westcoast1000 on Sep 09, 2022 1:37pm
Thanks. I was hoping for a bit of interpretation also.
Comment by Noteable on Sep 09, 2022 4:57pm
"Recent clinical data in breast and pancreatic cancer highlight pelareorep's multifaceted mechanism of action and the broad therapeutic benefits it confers," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc. "Results from AWARE-1 showed pelareorep activating cancer-killing T cells and modifying HR+/HER2- breast tumor microenvironments in ...more  
Comment by westcoast1000 on Sep 09, 2022 6:22pm
Thank you, Noteable. That is very helpful.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities